TrialPediatric nephrology (Berlin, Germany)2025

Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.

Alicia Fayad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.